CL-13

CL-13 is a butyrylcholinesterase (BChE) inhibitor, with an IC50 of 1.15 μM, and a selectivity index (SI) of 9.2 for acetylcholinesterase. CL-13 shows antioxidant activity in SH-SY5Y cells (DPPH EC50 = 47.01 μM) and has the ability to chelate metals involved in Aβ aggregation and/or oxidative stress, showing no neurotoxicity at 50 μM. CL-13 can reverse cognitive impairment caused by scopolamine without affecting the mice's motor skills[1].

Product Specifications

UNSPSC

12352005

Target

Amyloid-β; Cholinesterase (ChE)

Type

Reference compound

Related Pathways

Neuronal Signaling

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cl-13.html

Smiles

S=C(N/N=C/C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1)NC2=C(C=CC=C3)C3=NC4=CC=CC=C42

Molecular Formula

C29H32N4OS

Molecular Weight

484.66

References & Citations

[1]Gleyton Leonel Silva Sousa, et al. Discovery of novel thiosemicarbazone-acridine targeting butyrylcholinesterase with antioxidant, metal complexing and neuroprotector abilities as potential treatment of Alzheimer's disease: In vitro, in vivo, and in silico studies. Eur J Med Chem. 2025 Jan 5:281:117030.